Shots:
- The EMA has accepted a submission to extend marketing authorization of Ebglyss (lebrikizumab) to pts (6mos. to <18yrs., weighing <40kg) with mod. to sev. atopic dermatitis
- Application was supported by interim data from the pediatric clinical program, incl. the ADorable-1 evaluating Ebglyss in pts (6mos. to <18yrs.), & the ADorable-2 LTE study assessing safety & efficacy during maintenance treatment
- In ADorable-1, Ebglyss met both co-primary and key 2EPs vs PBO, delivering meaningful improvements in skin clearance, disease severity, itch, and quality of life, with a consistent safety profile
Ref: Businesswire | Image: Almirall | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
